Table 3.
Drug‐Gene interaction
| Current treatment | Previous treatment | Function | Metabolism | Reference |
|---|---|---|---|---|
| Citalopram | SSRI antidepressant | CYP2C19 | Uckun et al., 2015 | |
| Lamitogrine | Anti‐epileptic (AED) | UGT1A4, UGT2B7, (ABCB1 & SLC22A1 transporter involvement) | Milosheska et al., 2016 | |
| Lacosamide | Anti‐epileptic (AED) | CYP2C19 (no difference in CYP2C19 poor metabolizers) | Kumar et al., 2017 | |
| Risperidone | Antipsychotic | CYD2D6 | Dodsworth et al., 2018 | |
| Aripiprazole | Antipsychotic | CYP2D6 | Lisbeth et al., 2016 | |
| Methylphenidate | Stimulant (ADHD, ADD) | Carboxylesterase 1 (CES1) | Kaddurah‐Daouk et al., 2018 | |
| Amphetamine & dextroamphetamine | Stimulant (ADHD) | CYP2D6 | Miranda‐G. et al., 2007 | |
| Dexamphetamine | Stimulant (ADHD) | CYP2D6 | Teh & Bertilsson, 2012 | |
| Catapres | Hypertension, ADHD, anxiety | CYP2D6 | Claessens et al., 2010 | |
| Gabapentin | Anticonvulsant | Not metabolized | Radulovic et al., 1995 | |
| Clonazepam | Anticonvulsant | CYP3A5, CYP3A4 | Tóth et al., 2016 | |
| Sertraline | SSRI antidepressant | CYP2B6, CYP2C19 | Yuce‐Artun et al., 2016 |
Pharmaceutical list of treatments for Patient 1 with metabolic pathways. Both current and previous treatments are included, and genes in which Patient 1 possesses a variant that affects metabolism are in bold.